Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Reminder Deadline for Stepan NYSESCL Stock Dividend Approaching

Elaine Mendonca by Elaine Mendonca
February 27, 2024
in Breaking News
0
Finance_ Trading ratings today (2)
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Investors have until Wednesday to buy Stepan (NYSE:SCL) stock if they want to receive the upcoming quarterly dividend of 37.5 cents per share. The ex-dividend date is on Thursday, so anyone who owns the stock before then will be eligible for the payout. Shareholders who hold SCL by the end of Wednesday’s trading session will qualify for the dividend, which is set to be distributed on March 15, 2024.

SCL Stock Price Update: February 26, 2024 – Analysis and Insights

On February 26, 2024, SCL stock experienced a slight decrease in its price, closing at $90.00. This represented a $1.01 drop from the previous market close, which equates to a 1.11% decrease in value. Despite this decrease, SCL is still trading in the middle of its 52-week range and above its 200-day simple moving average.

The stock remained unchanged in after-hours trading, indicating that investors may be taking a wait-and-see approach before making any significant moves. Investors should always conduct thorough research and analysis before making any investment decisions. By staying informed and staying disciplined in their investment strategies, investors can make more informed decisions and potentially achieve greater success in the stock market.

SCL Stock Performance Analysis: Revenue Decline and Net Loss Reported in Fourth Quarter

On February 26, 2024, SCL stock experienced a mixed performance based on the latest financial data provided by CNN Money. The company reported a total revenue of $2.33 billion for the past year, which marked a 16.14% decrease compared to the previous year. In the fourth quarter, the total revenue was $532.13 million, reflecting a 5.35% decrease from the previous quarter.

In terms of net income, SCL reported $40.20 million for the past year, representing a significant 72.68% decrease from the previous year. However, in the fourth quarter, the company reported a net loss of $1.19 million, which was an improvement from the previous quarter.

Earnings per share (EPS) for SCL stood at $1.75 for the past year, showing a 72.57% decrease from the previous year. In the fourth quarter, the company reported a negative EPS of -$0.05, which remained flat compared to the previous quarter.

Tags: SCL
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Credit

Trustco Bank Declares Quarterly Dividend of 36 Cents per Share

Short Interest in Crown Holdings NYSE CCK Declines by 83

From Novice to Expert: Navigating the Cryptocurrency Learning Curve

Title Milestone Pharmaceuticals Inc NASDAQ MIST Surges on Plans to Resubmit NDA for Etripamil

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com